Pharmaceuticals, Biotechnology and Life Sciences
Galapagos has discovered GLPG3312, a first generation compound against a novel and undisclosed inflammation target class, and it started Phase 1 trial.
Basilea Pharmaceutica posted preliminary revenue for the financial year 2018, which is expected to increase by 31% over 2017 to about CHF133 million (€118.37M), from the last year’s CHF101.5 million (€90.3M).
Axsome Therapeutics’ AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD), the company said Monday.
Adverum Biotechnologies, a California-based ophthalmology and rare diseases focused biotech company, expects to provide an update on enrollment from the OPTIC phase 1 clinical trial in the first half of 2019, and interim data on the three cohorts from the OPTIC phase 1 clinical trial by the first quarter of 2020, it said in an outlook for 2019.
New York-based cancer therapeutics company, Stelexis Therapeutics has closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.
AstraZeneca has reached a clinical development milestone with immuno-oncology candidate AZD4635, thus triggering a $15 million payment to its partner, Sosei Group.
4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release
Orexo AB’s nasal spray formulations for opioid overdose reversal has been compared to Narcan in a study, in which it showed similar or better results, the company said in a press release on Monday.
Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.
Neumentum said Monday that findings from its phase I study of NTM-001 (pre-mixed bag ketorolac for continuous infusion), confirmed the investigational non-opioid pain treatment performs as it predicted in healthy adult volunteers.